Revenue ($USD) : $425,174,000
R&D spend : $54,418,000
Employees : 1,215
Fiscal year end : 12/31/2023
CEO : Kevin Thornal

www.nevro.com

Nevro provides pacemaker-like spinal cord stimulation systems for pain relief. The company started 2024 strong on the product front, with coverage wins for its painful diabetic neuropathy treatment and FDA clearance for a sacroiliac joint fusion device. However, with layoffs in January and questions over the company’s path to growth, the company announced in August that it’s looking at strategic options that could include partnerships, mergers or a sale. –SW